Hantavirus gp Specific Neutra™ Antibody Products

Are you struggling with inefficient antibody validation or delays in neutralizing antibody discovery against hantavirus? Creative Biolabs' hantavirus gp specific Neutra™ antibody products leverage advanced recombinant protein engineering and high-throughput epitope mapping to deliver rigorously validated, high-affinity antibodies. These tools enable rapid detection, mechanistic studies, and therapeutic candidate screening, streamlining your path from target validation to clinical translation.

Introduction to Hantavirus gp

The hantavirus envelope polyprotein, hereafter referred to as hantavirus gp, is a critical structural component responsible for viral entry and pathogenesis. Comprising two glycoprotein domains, G1 and G2, it mediates host cell adhesion and membrane fusion, making it indispensable for viral infectivity.

• Basic Information

Hantavirus gp is a surface glycoprotein expressed during viral assembly and maturation. Its conservation across hantavirus strains, including Hantaan and Seoul virus, underscores its central role in viral entry. The gp precursor undergoes post-translational cleavage to yield mature G1 and G2 subunits, which coordinate receptor binding and pH-dependent fusion with host endosomes.

• Structural Insights

The gp complex forms a trimeric spike on the viral envelope. G1 contains receptor-binding domains (RBDs) that interact with β3 integrins and other host factors, while G2 facilitates membrane fusion through conformational rearrangements triggered by endosomal acidity. Cryo-EM studies reveal dynamic structural transitions in gp during viral entry, highlighting potential neutralizing epitopes.

• Related Signaling Pathways

Hantavirus gp engagement disrupts endothelial cell integrity by modulating pathways such as VEGF and TGF-β, contributing to vascular leakage in hemorrhagic diseases. Additionally, gp-mediated immune evasion involves antagonism of IFN-I signaling, enhancing viral persistence.

Fig.1 Evasion of the innate immune response by hantavirus.¹

• Associated Pathologies

Hantavirus gp is central to two severe syndromes: Hemorrhagic Fever with Renal Syndrome (HFRS) and hantavirus Pulmonary Syndrome (HPS). Both diseases involve vascular dysfunction and high mortality rates, with gp-driven endothelial damage and immune hyperactivation exacerbating clinical outcomes.

Applications of Anti-Hantavirus gp Neutralizing Antibodies

• Therapeutic Intervention

Neutralizing antibodies are pivotal in post-exposure prophylaxis and treatment. Early administration of high-affinity anti-gp antibodies reduces viral load and mitigates end-organ damage in preclinical models, offering a promising strategy for curbing HFRS and HPS progression.

• Diagnostic Assay Development

High-specificity antibodies enable rapid, point-of-care detection of hantavirus gp in patient sera or environmental samples. This supports outbreak surveillance and early diagnosis, critical for containment in endemic regions.

• Vaccine Efficacy Evaluation

Anti-gp antibodies serve as correlates of protection in vaccine trials. Quantifying neutralizing titers post-vaccination provides actionable data for optimizing immunogen design and dosing regimens.

Our Anti-Hantavirus gp Antibodies

Neutralizing antibodies against hantavirus gp inhibit viral entry by blocking receptor interaction (G1-targeted) or preventing fusion (G2-targeted). Creative Biolabs' antibodies are engineered for exceptional specificity through phage display libraries and epitope binning, ensuring robust performance in:

- Viral neutralization assays: Quantify antibody potency via plaque reduction.

- Structural studies: Map conformational epitopes using cryo-EM and X-ray crystallography.

- Diagnostic development: Detect gp in clinical samples with ultra-sensitive WB and ELISA platforms.

Creative Biolabs delivers rigorously validated hantavirus gp-specific antibodies, combining cutting-edge protein engineering with scalable production platforms. Our products empower researchers to accelerate therapeutic discovery, refine diagnostic tools, and advance vaccine development.

Contact our scientific team today to discuss your project requirements and explore tailored solutions for your hantavirus research challenges.

REFERENCE

1. Zhang, Yusi, et al. "Viruses run: the evasion mechanisms of the antiviral innate immunity by hantavirus." Frontiers in microbiology 12 (2021): 759198. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2021.759198